nach oben

International Journal of Hematology

Erschienen in:

01.12.2011 | Review Article

Biological aspects of angiogenesis in multiple myeloma

verfasst von: Eléonore Otjacques, Marilène Binsfeld, Agnes Noel, Yves Beguin, Didier Cataldo, Jo Caers

Erschienen in: International Journal of Hematology | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

Multiple myeloma (MM) is a hematological malignancy characterized by the aberrant expansion of malignant plasma cells within the bone marrow (BM). One of the hallmarks of this disease is the close interaction between myeloma cells and neighboring cells within the BM. Angiogenesis, through the activation of endothelial cells, plays an essential role in MM biology. In the current review, we describe the angiogenesis process in MM by identifying the interacting cells, the pro- and anti-angiogenic cytokines modulated, and the extracellular matrix degrading proteases liable to participate in the pathophysiology. Finally, we highlight the impact of hypoxia (through hypoxia-inducible factor-1) and constitutive activation of nuclear factor-κB in this tumor-induced neo-vascularization.

Bray F, et al. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer. 2002;38(1):99–166.PubMedCrossRef

Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol. 2006;134(6):573–89.PubMedCrossRef

Caers J, et al. Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment. Bull Cancer. 2008;95(3):301–13.PubMed

Mattioli M, et al. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene. 2005;24(15):2461–73.PubMedCrossRef

Kyle RA, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564–9.PubMedCrossRef

Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249–57.PubMedCrossRef

Jakob C, et al. Angiogenesis in multiple myeloma. Eur J Cancer. 2006;42(11):1581–90.PubMedCrossRef

Rajkumar SV, et al. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia. 1999;13(3):469–72.PubMedCrossRef

Vacca A, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol. 1994;87(3):503–8.PubMedCrossRef

10.

Laroche M, et al. Increased vascularization in myeloma. Eur J Haematol. 2001;66(2):89–93.PubMedCrossRef

11.

Asosingh K, et al. Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity. Blood. 2004;103(8):3131–7.PubMedCrossRef

12.

Perez-Atayde AR, et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997;150(3):815–21.PubMed

13.

Sezer O, et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol. 2000;79(10):574–7.PubMedCrossRef

14.

Rajkumar SV, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res. 2000;6(8):3111–6.PubMed

15.

Rajkumar SV, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res. 2002;8(7):2210–6.PubMed

16.

Alexandrakis MG, et al. The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma. J Clin Pathol. 2004;57(8):856–60.PubMedCrossRef

17.

Baeriswyl V, Christofori G. The angiogenic switch in carcinogenesis. Semin Cancer Biol. 2009;19(5):329–37.PubMedCrossRef

18.

Kumar S, et al. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood. 2004;104(4):1159–65.PubMedCrossRef

19.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.PubMedCrossRef

20.

Pour L, et al. Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response. Ann Hematol. 2010;89(4):385–9.PubMedCrossRef

21.

Fujii R, Yaccoby S, Epstein J. Control of myeloma growth with the anti-angiogenic agent endostatin. Blood. 2002;96:360a.

22.

Urbanska-Rys H, Robak T. High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment. Mediators Inflamm. 2003;12(4):229–35.PubMedCrossRef

23.

De Raeve H, et al. Angiogenesis and the role of bone marrow endothelial cells in haematological malignancies. Histol Histopathol. 2004;19(3):935–50.PubMed

24.

Ribatti D. The discovery of endothelial progenitor cells. An historical review. Leuk Res. 2007;31(4):439–44.PubMedCrossRef

25.

Vacca A, et al. Endothelial cells in the bone marrow of patients with multiple myeloma. Blood. 2003;102(9):3340–8.PubMedCrossRef

26.

Asahara T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275(5302):964–7.PubMedCrossRef

27.

Rafii S. Circulating endothelial precursors: mystery, reality, and promise. J Clin Invest. 2000;105(1):17–9.PubMedCrossRef

28.

Suda T, Takakura N, Oike Y. Hematopoiesis and angiogenesis. Int J Hematol. 2000;71(2):99–107.PubMed

29.

Lyden D, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001;7(11):1194–201.PubMedCrossRef

30.

Yin AH, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 1997;90(12):5002–12.PubMed

31.

Miraglia S, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood. 1997;90(12):5013–21.PubMed

32.

Zhang H, et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood. 2005;105(8):3286–94.PubMedCrossRef

33.

Dominici M, et al. Angiogenesis in multiple myeloma: correlation between in vitro endothelial colonies growth (CFU-En) and clinical–biological features. Leukemia. 2001;15(1):171–6.PubMedCrossRef

34.

Wang X, Zhang Z, Yao C. Angiogenic activity of mesenchymal stem cells in multiple myeloma. Cancer Invest. 2011;29(1):37–41.PubMedCrossRef

35.

Scavelli C, et al. Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. Oncogene. 2008;27(5):663–74.PubMedCrossRef

36.

Caers J, et al. Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells. Leukemia. 2007;21(7):1580–4.PubMedCrossRef

37.

Dankbar B, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor–stromal cell interactions in multiple myeloma. Blood. 2000;95(8):2630–6.PubMed

38.

Barille S, et al. Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood. 1997;90(4):1649–55.PubMed

39.

Urashima M, et al. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood. 1997;90(2):754–65.PubMed

40.

Borset M, et al. Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood. 1996;88(10):3998–4004.PubMed

41.

Hose D, et al. Induction of angiogenesis by normal and malignant plasma cells. Blood. 2009;114(1):128–43.PubMedCrossRef

42.

Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med. 2005;9(4):777–94.PubMedCrossRef

43.

Vacca A, et al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica. 2003;88(2):176–85.PubMed

44.

Podar K, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 2001;98(2):428–35.PubMedCrossRef

45.

Uchiyama H, et al. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood. 1993;82(12):3712–20.PubMed

46.

Chauhan D, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood. 1996;87(3):1104–12.PubMed

47.

Kim I, et al. Cell surface expression and functional significance of adhesion molecules on human myeloma-derived cell lines. Br J Haematol. 1994;87(3):483–93.PubMedCrossRef

48.

Ribatti D, Nico B, Vacca A. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene. 2006;25(31):4257–66.PubMedCrossRef

49.

Birchmeier C, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4(12):915–25.PubMedCrossRef

50.

Maulik G, et al. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev. 2002;13(1):41–59.PubMedCrossRef

51.

Hose D, et al. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood. 2009;113(18):4331–40.PubMedCrossRef

52.

Seidel C, et al. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood. 1998;91(3):806–12.PubMed

53.

Derksen PW, et al. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia. 2003;17(4):764–74.PubMedCrossRef

54.

Andersen NF, et al. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol. 2005;128(2):210–7.PubMedCrossRef

55.

Alexandrakis MG, et al. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity. Am J Hematol. 2003;72(4):229–33.PubMedCrossRef

56.

Basilico C, Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res. 1992;59:115–65.PubMedCrossRef

57.

Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev. 1993;73(1):161–95.PubMed

58.

Ribatti D, et al. In vivo angiogenic activity of urokinase: role of endogenous fibroblast growth factor-2. J Cell Sci. 1999;112(Pt 23):4213–21.PubMed

59.

Vacca A, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 1999;93(9):3064–73.PubMed

60.

Bisping G, et al. Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood. 2003;101(7):2775–83.PubMedCrossRef

61.

Noel A, Jost M, Maquoi E. Matrix metalloproteinases at cancer tumor–host interface. Semin Cell Dev Biol. 2008;19(1):52–60.PubMedCrossRef

62.

Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer. 2003;3(6):422–33.PubMedCrossRef

63.

Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res. 2005;65(10):3967–79.PubMedCrossRef

64.

Monteiro Torres PH, Limaverde Soares Costa Sousa G, Pascutti PG. Structural analysis of the N-terminal fragment of the antiangiogenic protein endostatin: a molecular dynamics study. Proteins. 2011;79(9):2684–92.

65.

Van Valckenborgh E, et al. Upregulation of matrix metalloproteinase-9 in murine 5T33 multiple myeloma cells by interaction with bone marrow endothelial cells. Int J Cancer. 2002;101(6):512–8.PubMedCrossRef

66.

Vanderkerken K, et al. Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev. 2003;194:196–206.PubMedCrossRef

67.

Alexandrakis MG, et al. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma. Clin Chim Acta. 2007;379(1–2):31–5.PubMedCrossRef

68.

Rocks N, et al. Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie. 2008;90(2):369–79.PubMedCrossRef

69.

Bret C, et al. Gene expression profile of ADAMs and ADAMTSs metalloproteinases in normal and malignant plasma cells and in the bone marrow environment. Exp Hematol. 2011;39:546–57.PubMedCrossRef

70.

Karadag A, Zhou M, Croucher PI. ADAM-9 (MDC-9/meltrin-gamma), a member of the a disintegrin and metalloproteinase family, regulates myeloma-cell-induced interleukin-6 production in osteoblasts by direct interaction with the alpha(v)beta5 integrin. Blood. 2006;107(8):3271–8.PubMedCrossRef

71.

Hideshima T, et al. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol. 2001;28(6):607–12.PubMedCrossRef

72.

Giuliani N, et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood. 2002;100(13):4615–21.PubMedCrossRef

73.

Martin SK, et al. Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1alpha in patients with multiple myeloma. Clin Cancer Res. 2006;12(23):6973–7.PubMedCrossRef

74.

Terpos E, et al. Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma. Leuk Lymphoma. 2005;46(12):1699–707.PubMedCrossRef

75.

Fisher LW, et al. Purification and partial characterization of small proteoglycans I and II, bone sialoproteins I and II, and osteonectin from the mineral compartment of developing human bone. J Biol Chem. 1987;262(20):9702–8.PubMed

76.

Caers J, et al. The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model. Br J Haematol. 2006;132(4):469–77.PubMed

77.

Colla S, et al. Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients. Leukemia. 2005;19(12):2166–76.PubMedCrossRef

78.

Brahimi-Horn MC, Pouyssegur J. Harnessing the hypoxia-inducible factor in cancer and ischemic disease. Biochem Pharmacol. 2007;73(3):450–7.PubMedCrossRef

79.

Wenger RH. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J. 2002;16(10):1151–62.PubMedCrossRef

80.

Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 2008;15(4):678–85.PubMedCrossRef

81.

Wang GL, et al. Hypoxia-inducible factor 1 is a basic helix–loop–helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA. 1995;92(12):5510–4.PubMedCrossRef

82.

Yoo YG, et al. An essential role of the HIF-1alpha-c-Myc axis in malignant progression. Ann NY Acad Sci. 2009;1177:198–204.PubMedCrossRef

83.

Zundel W, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 2000;14(4):391–6.PubMed

84.

Hu Y, et al. Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan. Mol Cancer Ther. 2009;8(8):2329–38.PubMedCrossRef

85.

Harrison JS, et al. Oxygen saturation in the bone marrow of healthy volunteers. Blood. 2002;99(1):394.PubMedCrossRef

86.

Colla S, et al. Low bone marrow oxygen tension and hypoxia-inducible factor-1alpha overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells. Leukemia. 2010;24(11):1967–70.PubMedCrossRef

87.

Asosingh K, et al. Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression. Haematologica. 2005;90(6):810–7.PubMed

88.

Zannettino AC, et al. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res. 2005;65(5):1700–9.PubMedCrossRef

89.

Martin SK, et al. Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica. 2010;95(5):776–84.PubMedCrossRef

90.

Maxwell PH, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271–5.PubMedCrossRef

91.

Hatzimichael E, et al. Von Hippel–Lindau methylation status in patients with multiple myeloma: a potential predictive factor for the development of bone disease. Clin Lymphoma Myeloma. 2009;9(3):239–42.PubMedCrossRef

92.

Eischen CM, et al. Disruption of the ARF-Mdm2–p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999;13(20):2658–69.PubMedCrossRef

93.

Modrich P, Lahue R. Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annu Rev Biochem. 1996;65:101–33.PubMedCrossRef

94.

Menssen A, Hermeking H. Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc Natl Acad Sci USA. 2002;99(9):6274–9.PubMedCrossRef

95.

Zhang J, et al. Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma. Cancer Res. 2009;69(12):5082–90.PubMedCrossRef

96.

Koong AC, et al. Hypoxic activation of nuclear factor-kappa B is mediated by a Ras and Raf signaling pathway and does not involve MAP kinase (ERK1 or ERK2). Cancer Res. 1994;54(20):5273–9.PubMed

97.

Karashima T, et al. Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. Clin Cancer Res. 2003;9(7):2786–97.PubMed

98.

Annunziata CM, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007;12(2):115–30.PubMedCrossRef

99.

Keats JJ, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007;12(2):131–44.PubMedCrossRef

100.

van Uden P, Kenneth NS, Rocha S. Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. Biochem J. 2008;412(3):477–84.PubMedCrossRef

101.

Jung YJ, et al. IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 2003;17(14):2115–7.PubMed

102.

Qiao Q, et al. NF-kappaB mediates aberrant activation of HIF-1 in malignant lymphoma. Exp Hematol. 2010;38(12):1199–208.PubMedCrossRef

103.

Nam SY, et al. A hypoxia-dependent upregulation of hypoxia-inducible factor-1 by nuclear factor-kappaB promotes gastric tumour growth and angiogenesis. Br J Cancer. 2011;104(1):166–74.PubMedCrossRef

104.

Kwon HC, et al. Clinicopathological significance of nuclear factor-kappa B, HIF-1 alpha, and vascular endothelial growth factor expression in stage III colorectal cancer. Cancer Sci. 2010;101(6):1557–61.PubMedCrossRef

105.

D’Amato RJ, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91(9):4082–5.PubMedCrossRef

106.

Vacca A, et al. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(23):5334–46.CrossRef

107.

Rajkumar SV, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005;106(13):4050–3.PubMedCrossRef

108.

Richardson PG, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006;108(10):3458–64.PubMedCrossRef

109.

Lentzsch S, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia. 2003;17(1):41–4.PubMedCrossRef

110.

Lu L, et al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res. 2009;77(2):78–86.PubMedCrossRef

111.

De Luisi A, et al. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. Clin Cancer Res. 2011;17(7):1935–46.PubMedCrossRef

112.

Mitra-Kaushik S, et al. Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants. Blood. 2004;104(3):802–9.PubMedCrossRef

113.

Roccaro AM, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 2006;66(1):184–91.PubMedCrossRef

114.

De Vos J, et al. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene. 2002;21(44):6848–57.PubMedCrossRef

115.

Munshi NC, et al. Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood. 2004;103(5):1799–806.PubMedCrossRef

116.

Bao H, et al. Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma. Int J Hematol. 2009;90(2):177–85.PubMedCrossRef

117.

Seckinger A, et al. Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene. 2009;28(44):3866–79.PubMedCrossRef

Titel: Biological aspects of angiogenesis in multiple myeloma
verfasst von: Eléonore Otjacques
Marilène Binsfeld
Agnes Noel
Yves Beguin
Didier Cataldo
Jo Caers
Publikationsdatum: 01.12.2011
Verlag: Springer Japan
Erschienen in: International Journal of Hematology / Ausgabe 6/2011
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-011-0963-z

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Biological aspects of angiogenesis in multiple myeloma

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2011

Successful treatment with gemtuzumab ozogamicin and donor lymphocyte infusion for acute myeloid leukemia relapsing after allogeneic stem cell transplantation

Cytokine profiles in relapsed multiple myeloma patients undergoing febrile reactions to lenalidomide

Analysis of 43 cases of Langerhans cell histiocytosis (LCH)-induced central diabetes insipidus registered in the JLSG-96 and JLSG-02 studies in Japan

Intravascular B-cell lymphoma with hypercalcemia as the initial presentation

Treatment of patients with hypothalamic-pituitary lesions as adult-onset Langerhans cell histiocytosis

Symptomatic severe hypertriglyceridaemia with asparaginase therapy in acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma: is rechallenging safe?

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie